share_log

Johnson & Johnson | 424B5: Prospectus

Johnson & Johnson | 424B5: Prospectus

强生 | 424B5：募资说明书
美股SEC公告 ·  05/14 06:10
Moomoo AI 已提取核心信息
Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the filing of a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) under Rule 424(b)(5) for the issuance of a series of new senior unsecured notes. The notes, denominated in euros, are to be offered in three tranches with varying maturities and interest rates, which have yet to be determined. The interest on these notes will be paid annually, beginning in 2025. The notes will rank equally with Johnson & Johnson's other unsecured and unsubordinated debt. The company intends to list the notes on the New York Stock Exchange (NYSE) and expects trading to commence within 30 days post-issue. The proceeds from the sale of the notes are intended...Show More
Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the filing of a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) under Rule 424(b)(5) for the issuance of a series of new senior unsecured notes. The notes, denominated in euros, are to be offered in three tranches with varying maturities and interest rates, which have yet to be determined. The interest on these notes will be paid annually, beginning in 2025. The notes will rank equally with Johnson & Johnson's other unsecured and unsubordinated debt. The company intends to list the notes on the New York Stock Exchange (NYSE) and expects trading to commence within 30 days post-issue. The proceeds from the sale of the notes are intended for general corporate purposes, which may include funding the acquisition of Shockwave Medical, Inc., subject to customary closing conditions and regulatory approvals. The offering is subject to market conditions, and the completion of the offering is not contingent upon the completion of the acquisition. The date of the prospectus supplement is May 14, 2024.
领先的医疗保健公司强生公司（JNJ.US）宣布根据第424（b）（5）条向美国证券交易委员会（SEC）提交初步招股说明书补充文件，以发行一系列新的优先无抵押票据。这些以欧元计价的票据将分三批发行，期限和利率各不相同，尚未确定。从2025年开始，这些票据的利息将每年支付。这些票据的排名将与强生公司的其他无抵押和无次级债务相同。该公司打算在纽约证券交易所（NYSE）上市，并预计将在发行后的30天内开始交易。出售票据的收益用于一般公司用途，其中可能包括为收购Shockwave Medical, Inc. 提供资金，但须遵守惯例成交条件和监管部门的批准。此次发行视市场情况而定，发行的完成不以收购完成为条件。招股说明书补充材料的发布日期为2024年5月14日。
领先的医疗保健公司强生公司（JNJ.US）宣布根据第424（b）（5）条向美国证券交易委员会（SEC）提交初步招股说明书补充文件，以发行一系列新的优先无抵押票据。这些以欧元计价的票据将分三批发行，期限和利率各不相同，尚未确定。从2025年开始，这些票据的利息将每年支付。这些票据的排名将与强生公司的其他无抵押和无次级债务相同。该公司打算在纽约证券交易所（NYSE）上市，并预计将在发行后的30天内开始交易。出售票据的收益用于一般公司用途，其中可能包括为收购Shockwave Medical, Inc. 提供资金，但须遵守惯例成交条件和监管部门的批准。此次发行视市场情况而定，发行的完成不以收购完成为条件。招股说明书补充材料的发布日期为2024年5月14日。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息